Aripiprazole and dehydroaripiprazole

Aripiprazole and dehydroaripiprazole measured by LC-MS/MS
Clinical details: 
Aripiprazole is an atypical antipsychotic with a novel structure. It is used at a dose of 10-15 mg once daily, up to a maximum of 30 mg/d. Aripiprazole undergoes extensive hepatic metabolism via CYP2D6 and CYP3A4 including dehydrogenation, hydroxylation, and N-dealkylation. Dehydroaripiprazole has pharmacological activity, and accumulates in plasma to ca. 40 % of the aripiprazole concentration at steady-state, which is achieved in about 14 days. The plasma half-life averages 75 h (aripiprazole) and 94 h (dehydroaripiprazole). Aripiprazole and dehydroaripiprazole assay is useful in assessing adherence and may help in dose optimisation, and if acute poisoning is suspected. A reference range of 150–300 µg/L of aripiprazole (60-120 µg/L dehydroaripiprazole) has been suggested (12 h post-dose sample).
Reference range: 


Synonyms or keywords: 
Sample type and Volume required: 
4 mL of ETDA whole blood is preferred (pre-dose or ‘trough’ sample). Serum or plasma can be used if required, but please avoid gel-separator tubes.
Turnaround time: 
5 working days
Storage and transport: 
Please refrigerate (if possible) if not sending immediately. Send by first class post.
Toxicology Department at King's Hospital
020 3299 5881
King's College Hospital
Bessemer Wing - 3rd Floor
Denmark Hill
London SE5 9RS
For clinical advice or interpretation of results, please contact the laboratory in the first instance.

Print as a PDF

Last updated: 03/10/2022